Renata Ferrarotto, MD

Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine

About Dr. Renata Ferrarotto

Dr. Ferrarotto is a Professor and Director of Head and Neck Oncology Clinical Research of Department of Thoracic/Head and Neck Medical. In this role, she dedicates time to patient care as well as to clinical and translational research. Her work focuses on clinical development of new personalized cancer therapies for patients with head and neck malignancies, with a particular interest in salivary gland cancers and other rarer tumor subtypes. She has conducted multiple investigator-initiated trials. Dr. Ferrarotto was a recipient of the MD Anderson Jeffrey Lee Cousins Fellowship in Lung Cancer in 2013, the ASCO Career Development Award in 2016, the Khalifa grant in 2016, a Stiefel grant in 2018, an Institutional Research Grant in 2020, three pilot grants from the Adenoid Cystic Carcinoma Research Foundation in 2000, 2021, and 2022, a DOD Impact Award in 2021, and an R03 grant in 2022.

Higher bacteria levels inside tumors can promote immunotherapy resistance in head and neck cancer

A micrograph of adenoid cystic carcinoma in the breast

Understanding adenoid cystic carcinoma: Symptoms, treatment and outlook

Present Title & Affiliation

Primary Appointment

Professor, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Dr. Ferrarotto’s work focuses on examining gene and protein profiles of adenoid cystic carcinoma (ACC), a common salivary gland cancer, and other types of head and neck tumors in order to identify alterations that can be targeted with suitable therapy regimens (targeted therapy or immunotherapy). To accomplish this, alterations of genes and proteins found in tumor samples are correlated with the patient’s individual tumor characteristics and clinical outcomes (disease progression and survival), then the effects of different drugs targeting the gene or protein of interest are examined in pre-clinical models, and finally the results obtained in the lab are used to develop and design clinical trials with new therapeutic regimens for patients. Dr. Ferrarotto has identified NOTCH1 as a potential therapeutic target in ACC and led the first biomarker-specific study in ACC investigating a NOTCH inhibitor in NOTCH-activated metastatic ACC. Her group has further completed the first comprehensive proteogenomic analysis of a large cohort of ACC with annotated clinicopathologic data, which could help stratify patients and identify potential biomarkers for co-targeting with NOTCH inhibitors. Currently, Dr. Ferrarotto is leading projects to investigate the impact of tumor immune microenvironment on treatment response in salivary gland/head and neck tumors, and to develop immunotherapy-based combination therapies to overcome drug resistance.

Clinical Interests

Dr. Ferrarotto is a medical oncologist dedicated to improving the quality and length of life of patients suffering from head and neck malignancies. Dr. Ferrarotto’s work centers in developing clinical trial with novel drug combinations and on identifying predictive biomarkers that can be used to select the patients that will benefit the most from targeted therapy and immunotherapy. Beyond the most common head and neck squamous cell carcinoma, Dr Ferrarotto has a special interest in rare cancers of the head and neck, particularly salivary gland cancers.

Education & Training

Degree-Granting Education

2006	Universidade Estadual de Campinas (UNICAMP), Campinas, BR, MD

Postgraduate Training

2012-2014	Clinical Fellowship, Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
2009-2012	Clinical Fellowship, Medical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil, Sao Paulo
2007-2009	Clinical Residency, Internal Medicine, Universidade de Sao Paulo (USP), Sao Paulo

Licenses & Certifications

2019	American Board of Internal Medicine Medical Oncology
2018	American Board of Internal Medicine
2016	Texas Medical Licensure

Experience & Service

Faculty Academic Appointments

Associate Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2023

Assistant Professor, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2018

Instructor, Cancer Medicine, Sirio Libanes Hospital, Sao Paulo, 2012 - 2012

Administrative Appointments/Responsibilities

Fellowship Program Director, Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2023

Director, Department of Thoracic/Head and Neck Medical Oncology, Head and Neck Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present

Other Professional Positions

Consultantships, Rgenta, 2024 - Present

Consultantships, BioAtla, Houston, Tx, 2023 - Present

Consultantships, Remix Therapeutics, Cambrige, MA, 2022

Consultantships, Sanofi, Houston, Tx, 2022

Consultantships, Regeneron Therapeutics, New York, NY, 2022

Consultantships, Eisai, Houston, Tx, 2022 - Present

Consultantships, Prelude Therapeutics, Houston, Tx, 2022 - 2023

Consultantships, Elevar Therapeutics, Houston, Tx, 2022

Consultantships, G1 Therapeutics, Houston, Tx, 2021

Consultantships, Merck, Houston, Tx, 2021

Consultantships, Ayala Pharmaceutical, Houston, Tx, 2021 - 2023

Consultantships, Guidepoint Global, Houston, Tx, 2021 - 2022

Consultantships, Bicara Therapeutics, Houston, Tx, 2020 - 2021

Consultantships, Intellisphere, Houston, Tx, 2020

Consultantships, Carevive Sytems, Houston, Tx, 2019 - 2020

Consultantships, Medscape, Chicago, IL, 2019 - 2020

Consultantships, Klus pharma, Houston, Tx, 2019 - 2019

Consultantships, Cellestia Biotech, Houston, Tx, 2018

Consultantships, Bristol-Myers Squibb, Houston, Tx, 2017

National Cancer Institute Rare Tumors Task Force, Head and Neck Cancer Steering Committee, Houston, TX, 2015 - 2018

Extramural Institutional Committee Activities

Member, Clinical Trials Network (CTN) Steering Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, MD Anderson Head & Neck Multidisciplinary Planning Conference planning committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, MD Anderson Advisory Council of Clinical Research Leaders (ACCRL) committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Faculty Search Committee, Department of Head Neck Surgery, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, MD Anderson Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, MD Anderson Data Safety Monitoring Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2021

Co-chair, Rakuten Strategic Alliance, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, MD Anderson Cancer Center Institutional Review Board 1, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Member, MD Anderson Cancer Center Faculty Senate, The University of Texas MD Anderson Cancer Center, 2016 - 2019

Member, MD Anderson Cancer Center Rare Tumor Working Group, The University of Texas MD Anderson Cancer Center, 2015 - Present

Medical Oncologist representative, MD Anderson Cancer Center Skull Base Working Group, The University of Texas MD Anderson Cancer Center, 2015 - Present

Medical Oncologist representative, MD Anderson Head and Neck Cancer Symptom Working Group, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Education Committee of the Department of Thoracic / Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 2014 - Present

Editorial Activities

Journal Editor, Review Editor of “Cancer Immunity and Immunotherapy”, part of the journal Frontiers in Immunology and Oncology, 2016 - Present

Honors & Awards

2025 - Present	Top 10% provider in the nation
2024 - Present	Top 10% provider in the nation
2023 - Present	Top 1% provider in the nation
2014	Methods in Clinical Cancer Research Workshop, Flims, Switzerland. Awarded study protocol: “Phase II trial of T-DM1 for recurrent or metastatic HER2 positive malignant salivary gland tumors”
2014	Trainee Excellence Award, The University of Texas MD Anderson Cancer Center
2014	Awarded trial protocol: “Phase II trial of OMP-52M51, a Notch1 inhibitor, in adenoid cystic carcinoma”, MD Anderson Clinical Research Design and Methods Workshop, Houston, TX
2013	Clinical Fellow Award, The Jeffrey Lee Cousins Fellowship in Lung Cancer, The University of Texas MD Anderson Cancer Center
2013	Trainee Research Day Poster Finalist, Postgraduate Basic Science Research, The University of Texas M. D. Anderson Cancer Center

Professional Memberships

North American Skull Base Society

2015 - Present

Southwest Oncology Group- SWOG

2014 - Present

International Rare Cancer Joint Initiative

2014 - Present

European Society of Medical Oncology

2012 - Present

International Association for the Study of Lung Cancer

2012 - 2016

American Society of Clinical Oncology

2011 - Present

Selected Presentations & Talks

Local Presentations

2015. Chemotherapy in Optimizing Function in Patients with Head and Neck Cancer. Conference. Chemotherapy in Optimizing Function in Patients with Head and Neck Cancer. Houston, TX, US.

Regional Presentations

2020. Chemotherapy for Head and Neck Cancer. Oral Oncology Symposium. Conference. Chemotherapy for Head and Neck Cancer. Oral Oncology Symposium, US.
2017. Immunotherapies Update in Head & Neck Cancer. Conference. Immunotherapies Update in Head & Neck Cancer, US.
2017. PARP1 Overexpression in Merkel Cell Carcinoma and Its Potential Clinical Implications. Conference. PARP1 Overexpression in Merkel Cell Carcinoma and Its Potential Clinical Implications. San Antonio, TX, US.
2017. Therapeutic Targets in Salivary Gland Malignancies. Conference. Therapeutic Targets in Salivary Gland Malignancies, US.

National Presentations

2023. Radiosensitivity signature in ACC of salivary glands origin is associated with ACC type II. Poster Presentation,. Conference. Radiosensitivity signature in ACC of salivary glands origin is associated with ACC type II. Poster Presentation,, US.
2023. Efficacy of NOTCH inhibitors relative to prior systemic therapy or observation in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Poster Presentation, 2023 ESMO Annual Meeting. Conference. Efficacy of NOTCH inhibitors relative to prior systemic therapy or observation in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Poster Presentation, 2023 ESMO Annual Meeting, US.
2023. AL101 Therapy in Patients with Recurrent/Metastatic (R/M) Adenoid Cystic Carcinoma (ACC): Final ACCURACY Trial Results and Meta-analysis of Clinical Outcomes. Poster Presentation. Conference. AL101 Therapy in Patients with Recurrent/Metastatic (R/M) Adenoid Cystic Carcinoma (ACC): Final ACCURACY Trial Results and Meta-analysis of Clinical Outcomes. Poster Presentation, US.
2023. TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype. Poster Presentation. Conference. TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype. Poster Presentation, US.
2023. Neoadjuvant Immunotherapy. Conference. Neoadjuvant Immunotherapy, US.
2023. Update on non-surgical treatment of advanced cutaneous cancer. Conference. Update on non-surgical treatment of advanced cutaneous cancer, US.
2023. Prognostic Factors and Systemic Treatment Options for Adenoid Cystic Carcinoma. Conference. Prognostic Factors and Systemic Treatment Options for Adenoid Cystic Carcinoma, US.
2023. Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Conference. Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), US.
2023. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. Conference. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results, US.
2023. Salivary gland adenoid cystic carcinoma: a complex entity. Conference. Salivary gland adenoid cystic carcinoma: a complex entity, US.
2023. Preliminary analysis of laryngeal organ function after single modality chemo/immunotherapy for T2-T3 laryngeal tumors in the Phase II iCOLP trial. Conference. Preliminary analysis of laryngeal organ function after single modality chemo/immunotherapy for T2-T3 laryngeal tumors in the Phase II iCOLP trial, US.
2022. New treatments for recurrent or metastatic salivary gland cancer. Conference. New treatments for recurrent or metastatic salivary gland cancer, US.
2022. Immunotherapy in the curative intent setting in HNSCC. Conference. Immunotherapy in the curative intent setting in HNSCC, US.
2022. Frontiers in Skull Base Surgery. Systemic Therapy of Major players. Conference. Frontiers in Skull Base Surgery. Systemic Therapy of Major players, US.
2022. Systemic Therapy in the Curative Setting for Head and Neck Squamous Cell Carcinoma. Conference. Systemic Therapy in the Curative Setting for Head and Neck Squamous Cell Carcinoma, US.
2022. Novel Systemic Treatment for Recurrent or Metastatic Salivary Cancers. Conference. Novel Systemic Treatment for Recurrent or Metastatic Salivary Cancers, US.
2022. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Conference. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN), US.
2022. Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations. Conference. Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations, US.
2022. Single-cell immune mapping of adenoid cystic carcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype. Conference. Single-cell immune mapping of adenoid cystic carcinoma (ACC) reveals potential therapeutic targets for the aggressive solid subtype, US.
2022. A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC). Conference. A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC), US.
2021. Immunotherapy and Advances in Medical Oncology. Conference. Immunotherapy and Advances in Medical Oncology, US.
2021. Integration of systemic therapy in the treatment of patients undergoing surgery for head and neck cancer. Conference. Integration of systemic therapy in the treatment of patients undergoing surgery for head and neck cancer, US.
2021. Novel Molecular Classification of Adenoid Cystic Carcinoma with Therapeutic Implications. Conference. Novel Molecular Classification of Adenoid Cystic Carcinoma with Therapeutic Implications, US.
2021. From bench to bedside in salivary gland tumors: is there any hope for adenoid cystic carcinoma. Conference. From bench to bedside in salivary gland tumors: is there any hope for adenoid cystic carcinoma, US.
2021. High-grade neuroendocrine carcinoma of the oropharynx: A rare entity with prognosis unaffected by HPV. Conference. High-grade neuroendocrine carcinoma of the oropharynx: A rare entity with prognosis unaffected by HPV, US.
2021. Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer. Conference. Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer, US.
2021. Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS. Conference. Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS, US.
2021. Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. Conference. Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers, US.
2020. TPExtreme randomized trial: Quality of Life (Qol) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Conference. TPExtreme randomized trial: Quality of Life (Qol) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), US.
2020. Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase Ill Metro-CIS study. Conference. Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase Ill Metro-CIS study, US.
2020. ACCURACY a Phase 2 trial of AL101 in subjects with recurrent/metastatic adenoid cystic carcinoma harboring Notch activating mutations, trial updates. Conference. ACCURACY a Phase 2 trial of AL101 in subjects with recurrent/metastatic adenoid cystic carcinoma harboring Notch activating mutations, trial updates, US.
2020. Integrative proteomic and transcriptomic analysis define adenoid cystic carcinoma subgroups with distinct therapeutic targets. Conference. Integrative proteomic and transcriptomic analysis define adenoid cystic carcinoma subgroups with distinct therapeutic targets. Scottsdale, AZ, US.
2020. Trilaciclib reduces the need for growth factors and red blood cell transfusions to manage chemotherapy-induced myelosuppression (Oral Presentation). Conference. Trilaciclib reduces the need for growth factors and red blood cell transfusions to manage chemotherapy-induced myelosuppression (Oral Presentation), US.
2020. et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). Poster discussion, abstract 6514. Conference. et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). Poster discussion, abstract 6514, US.
2020. ACCURACY a Phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic adenoid cystic carcinoma harboring Notch activating mutations. Abstract # 4418. Mini Oral. Conference. ACCURACY a Phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic adenoid cystic carcinoma harboring Notch activating mutations. Abstract # 4418. Mini Oral, US.
2019. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous. Conference. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous, Barcelona, US.
2019. ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data. Conference. ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data, US.
2019. Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Conference. Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan, US.
2019. AL101 mediated tumor inhibition in Notch mutated ACC PDX models. Conference. AL101 mediated tumor inhibition in Notch mutated ACC PDX models, US.
2019. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (Poster). Conference. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (Poster), US.
2019. ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations. Conference. ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations, US.
2018. Clinical utility of plasma cell-free DNA (cfDNA) in anaplastic thyroid carcinoma (ATC)(Poster). Conference. Clinical utility of plasma cell-free DNA (cfDNA) in anaplastic thyroid carcinoma (ATC)(Poster). Washington, DC, US.
2018. Immuno-Radiotherapy: A new approach? Clinical Science Symposium, Integrating immunotherapy into standard of care for Head and Neck Cancer. Conference. Immuno-Radiotherapy: A new approach? Clinical Science Symposium, Integrating immunotherapy into standard of care for Head and Neck Cancer, US.
2018. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. Conference. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies, US.
2018. Using mobile and sensor technology to identify early dehydration risk in head and neck cancer patients undergoing radiation treatment: Impact on symptoms. (Poster). Conference. Using mobile and sensor technology to identify early dehydration risk in head and neck cancer patients undergoing radiation treatment: Impact on symptoms. (Poster), US.
2018. Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival. Conference. Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival, US.
2018. Immunotherapy in Head and Neck Cancer. Invited to present at the 15th Annual Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Symposium. Conference. Immunotherapy in Head and Neck Cancer. Invited to present at the 15th Annual Dan L. Duncan Comprehensive Cancer Center (DLDCCC) Symposium, US.
2018. Chemotherapy for Advanced Nasopharyngeal Carcinoma--MDACC Institutional Experience. Conference. Chemotherapy for Advanced Nasopharyngeal Carcinoma--MDACC Institutional Experience. Orlando, FL, US.
2018. Checkpoint inhibitors assessment in oropharynx carcinoma. Conference. Checkpoint inhibitors assessment in oropharynx carcinoma. San Francisco, CA, US.
2017. Immunotherapy for the Treatment of Head and Neck Cancer. Conference. Immunotherapy for the Treatment of Head and Neck Cancer, US.
2017. Efficacy of Pembrolizumab in Patients with Cutaneous Squamous Cell Carcinoma. Conference. Efficacy of Pembrolizumab in Patients with Cutaneous Squamous Cell Carcinoma, US.
2017. Notch in ACC and hematopoiesis. Conference. Notch in ACC and hematopoiesis, US.
2017. Association of activating NOTCH1 mutations in adenoid cystic carcinoma with shorter progression-free survival to systemic therapy. Conference. Association of activating NOTCH1 mutations in adenoid cystic carcinoma with shorter progression-free survival to systemic therapy. Chicago, IL, US.
2017. Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. Conference. Prognostic factors and survival in adenoid cystic carcinoma of the sinonasal cavity. San Diego, CA, US.
2017. PARP1 as a potential therapeutic target in Merkel cell carcinoma. Conference. PARP1 as a potential therapeutic target in Merkel cell carcinoma. San Diego, CA, US.
2017. Preliminary results of the clinical trials testing trilaciclib (G1T28), a CDK4/6 inhibitor, in combination with first or second line chemotherapy in patients with metastatic small cell lung cancer. Conference. Preliminary results of the clinical trials testing trilaciclib (G1T28), a CDK4/6 inhibitor, in combination with first or second line chemotherapy in patients with metastatic small cell lung cancer, NY, US.
2017. Nivolumab and ISA101 Vaccine in Patients with Incurable HPV-16+ Cancer. Conference. Nivolumab and ISA101 Vaccine in Patients with Incurable HPV-16+ Cancer, US.
2016. Harvesting High-hanging Fruit: Targeted Therapy for BRAF mutant and BRAF wild-type Anaplastic Thyroid Cancer (ATC). Conference. Harvesting High-hanging Fruit: Targeted Therapy for BRAF mutant and BRAF wild-type Anaplastic Thyroid Cancer (ATC). Denver, CO, US.
2016. Outcomes for esthesioneuroblastoma treated with neoadjuvant chemotherapy. Conference. Outcomes for esthesioneuroblastoma treated with neoadjuvant chemotherapy. Seattle, WA, US.
2016. Patterns of Failure in Anaplastic Thyroid Cancer. Conference. Patterns of Failure in Anaplastic Thyroid Cancer. Boston, MA, US.
2015. Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors. Conference. Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors. Bostom, MA, US.
2015. MD Anderson Oncology Expert Advisory TM System (OEATM): A Cognitive computing Recommendations Application (App) for Lung Cancer. Conference. MD Anderson Oncology Expert Advisory TM System (OEATM): A Cognitive computing Recommendations Application (App) for Lung Cancer, US.
2015. Notch 1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival. Conference. Notch 1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival, US.
2014. Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch-1) administered intravenously to patients with certain advanced solid tumors. Conference. Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch-1) administered intravenously to patients with certain advanced solid tumors, US.
2013. Identifying biomarkers of sensitivity to polo-like kinase inhibitors in Non-Small-Cell Lung Cancer (NSCLC). Conference. Identifying biomarkers of sensitivity to polo-like kinase inhibitors in Non-Small-Cell Lung Cancer (NSCLC), US.
2013. Identifying biomarkers of sensitivity to polo-like kinase (Plk) inhibitors in Non-Small-Cell Lung Cancer (NSCLC). Conference. Identifying biomarkers of sensitivity to polo-like kinase (Plk) inhibitors in Non-Small-Cell Lung Cancer (NSCLC). Santa Monica, CA, US.
2012. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. Conference. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly, US.
2012. Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly. Conference. Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly, US.
2011. Combination of capecitabine and oxaliplatin (CapOx) is an effective option for the treatment of neuroendocrine tumors (NET). Conference. Combination of capecitabine and oxaliplatin (CapOx) is an effective option for the treatment of neuroendocrine tumors (NET), US.
2011. A multicenter, multinational analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (nCRC). Conference. A multicenter, multinational analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (nCRC), US.

International Presentations

2017. Circulating BRAFV600E cell-free DNA (cfDNA) detected by droplet digital PCR (ddPCR) as a biomarker for monitoring response to therapy in the management of BRAF mutated (BRAFm) anaplastic thyroid carcinoma (ATC) patients (pts). Conference. Circulating BRAFV600E cell-free DNA (cfDNA) detected by droplet digital PCR (ddPCR) as a biomarker for monitoring response to therapy in the management of BRAF mutated (BRAFm) anaplastic thyroid carcinoma (ATC) patients (pts), CA.
2016. Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch-1) administered intravenously to patients with certain advanced solid tumors. Presented at the 26th EORTC-NCI-AACR meeting, Barcelona, Spain, Nov/14. Conference. Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch-1) administered intravenously to patients with certain advanced solid tumors. Presented at the 26th EORTC-NCI-AACR meeting, Barcelona, Spain, Nov/14. Vienna, AT.
2016. The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth. Conference. The CDK4/6 Inhibitor G1T28 Protects Immune Cells from Cisplatin-Induced Toxicity in vivo and Inhibits SCLC Tumor Growth. Vienna, AT.
2016. a cyclin dependent kinase 4/6 inhibitor, in combination with topotecan for previously treated small cell lung cancer (SCLC): preliminary results. Conference. a cyclin dependent kinase 4/6 inhibitor, in combination with topotecan for previously treated small cell lung cancer (SCLC): preliminary results. Vienna, AT.
2016. a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. Conference. a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. Munich, DE.
2009. Combination of capecitabine and oxaliplatin demonstrate clinical activity in neuroendocrine carcinoma. Conference. Combination of capecitabine and oxaliplatin demonstrate clinical activity in neuroendocrine carcinoma. Fortaleza, BR.

Formal Peers

2023. Current and novel systemic therapies for salivary gland carcinomas. Visiting, US.
2023. Dealing with ACC Lung Metastasis. Visiting, US.
2023. Therapeutic Targets in ACC. Visiting, US.
2023. Management of advanced salivary gland malignancies. Visiting, US.
2023. Sinonasal & Skull Base Malignancies. Visiting, US.
2022. Ferrarotto R, Treatment of Salivary Gland Carcinomas. Invited, US.
2022. Ferrarotto R Update on Management of head and neck cancers. Invited, FL, US.
2022. Ferrarotto R, Keynote Lecture: Adenoid cystic carcinoma. What we have still to know? Current management and future challenges in Salivary Gland Cancers. Invited, US.
2022. Ferrarotto R, Novel Molecular Classification of Adenoid Cystic Carcinoma with Therapeutic Implications. Invited, US.
2021. Ferrarotto R, Meet the Professor sponsored by Merck. The importance of IO upfront in metastatic/recurrent HNSCC in 1 L. Visiting, US.

Less

Grant & Contract Support

Date:	2024 - Present
Title:	“Harnessing Tumor and Circulating-Free DNA Methylation for Prognosis and Treatment Stratification in Adenoid Cystic Carcinoma”,
Funding Source:	NIH/NCI
Role:	PI

Date:	2022 - 2024
Title:	Exploring biomarkers of clinical benefit to VEGFR inhibitor combined with PD-L1 inhibitor in recurrent/metastatic Adenoid Cystic Carcinoma
Funding Source:	NIH/NIDCR
Role:	PI
ID:	R03/GRANT13296603

Date:	2022 - 2023
Title:	“Oral Cavity Carcinoma Immune Microenvironment and its Impact on Clinical Outcome”
Funding Source:	AHNS Pilot Grant to Luana Sosa
Role:	Mentor

Date:	2022 - 2023
Title:	“Landscape of the immune microenvironment in HPV-related oropharynx squamous cell carcinoma and its impact on outcomes following chemoradiotherapy” (CRT
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	Mentor

Date:	2021 - 2022
Title:	“Deep Learning Image Analysis Algorithms to Improve Oral Cancer Risk Assessment for Oral Potentially Malignant Disorders”
Funding Source:	NIH
Role:	Co-I

Date:	2021 - 2025
Title:	“Characterization and targeting NOTCH activated Adenoid Cystic Carcinoma (ACC)”
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	PI
ID:	GRANT13192702/W81XWH-20-PRCRP-IPA

Date:	2021 - 2022
Title:	"Imaging features and natural history of metastatic adenoid cystic carcinoma"
Funding Source:	Adenoid Cystic Carcinoma Research Foundation (ACCRF),
Role:	PI

Date:	2020 - 2021
Title:	"Characterization of the immune microenvironment of adenoid cystic carcinoma using imaging mass cytometry
Funding Source:	Adenoid Cystic Carcinoma Research Foundation (ACCRF),
Role:	PI

Date:	2020 - 2021
Title:	Awarded research project "Decipher immune responsiveness in oropharynx cancer patients treated with neoadjuvant immune checkpoint inhibitors"
Funding Source:	Institutional Research Grant (IRG),
Role:	PI

Date:	2019 - 2020
Title:	"Explore the activity of combining AL101 with retinoic acid and inhibitors of BCL2 and multi tyrosine kinases in adenoid cystic carcinoma"
Funding Source:	Adenoid Cystic Carcinoma Research Foundation (ACCRF)
Role:	PI

Date:	2018 - 2020
Title:	“Understanding immunological mechanisms induced by dual checkpoint inhibition in oropharynx cancer”
Funding Source:	Stiefel Grant
Role:	PI

Date:	2017 - 2022
Title:	“Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC”,
Funding Source:	NIH
Role:	Co-I
ID:	U01CA213273-01A1

Date:	2017 - 2020
Title:	"Novel therapeutic strategies for Notch activated adenoid cystic carcinoma"
Funding Source:	Khalifa Scholar
Role:	PI

Date:	2016 - 2019
Title:	“Optimizing Chemoradiation Strategies by Tumor Metabolism Interrogation”, RP170366
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2016 - 2019
Title:	“Notch1 as a therapeutic target in adenoid cystic carcinoma”
Funding Source:	2016 Conquer Cancer Foundation Career Development Award
Role:	PI

Date:	2016 - 2018
Title:	“Checkpoint Inhibitors Assessment in Oropharynx Carcinoma’
Funding Source:	Stiefel Grant, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2013 - Present
Title:	The Ryan W. Smith Endowed Fund for Adenoid Cystic Carcinoma
Funding Source:	The Ryan W. Smith Endowed Fund
Role:	Co-I

Title:	“Exploring the tumor immune microenvironment and ctDNA dynamics associated with durable pathologic complete response to immunochemotherapy in larynx cancer”, Oncology Translational Studies Program
Funding Source:	Merck
Role:	PI

Title:	“Identifying biomarkers predictive of durable pathologic complete response to immuno-chemotherapy in larynx cancer”,
Funding Source:	Sanofi iAwards
Role:	PI

Selected Publications

Peer-Reviewed Articles

Dagher, R, Khalaf, A, Ferrarotto, R, Learned, KO. Immunotherapy and Targeted Therapy Considerations in Head and Neck Oncology. Radiologic Clinics of North America 64(1):35-49, 2026. e-Pub 2026. PMID: 41233057.
Trinconi Cunha, M, Sewastjanow-Silva, M, Holsinger, F, Garden, AS, El-Naggar, AK, Myers, JN, Lewin, JS, Gillenwater, AM, Lee, JJ, Khuri, F, Diaz Jr, EM, Ferrarotto, R. Chemotherapy alone for stage II–IVa laryngeal squamous cell carcinoma. Cancer 131(23), 2025. e-Pub 2025. PMID: 41250807.
Wotman MT, Khalaf A, Wang K, Meric-Bernstam F, Gillison ML, Akhave N, Kerrigan K, Ferrarotto R. Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series. J Natl Compr Canc Netw:1-5, 2025. e-Pub 2025. PMID: 41213241.
Lu TJ, Fan J, Guimaraes de Sousa L, Sagiv O, Hernandez S, Bolanos Gomez L, Akhave N, Ferrarotto R, Esmaeli B. PD-1 Inhibitors for Periocular Squamous Cell Carcinoma With Perineural Spread to the Orbit and Skull Base. Ophthalmic Plast Reconstr Surg 41(6):664-670, 2025. e-Pub 2025. PMID: 40237556.
Allen DZ, Gross N, Nader ME, Ferrarotto R, Amit M, Nagarajan P, Gidley P. Neoadjuvant Immunotherapy for Periauricular Cutaneous Squamous Cell Carcinoma. Head Neck, 2025. e-Pub 2025. PMID: 41137728.
Siqueira, JM, Heguedusch, D, Cunha, MT, Guimares de Sousa, L, Marques-Piubelli, ML, Carvalho, GL, Hoff, CO, Bonini, F, Mitani, Y, Spiotto, MT, Goepfert, RP, Nunes, FD, De Matos, LL, Kowalski, LP, McGrail, DJ, El-Naggar, AK, Ferrarotto, R. Exploring TROP2 expression in oropharyngeal squamous cell carcinoma. Oral Oncology 169, 2025. e-Pub 2025.
Siqueira, JM, Heguedusch, D, Cunha, MT, Guimares de Sousa, L, Marques-Piubelli, ML, Carvalho, GL, Hoff, CO, Bonini, F, Mitani, Y, Spiotto, MT, Goepfert, RP, Nunes, FD, De Matos, LL, Kowalski, LP, McGrail, DJ, El-Naggar, AK, Ferrarotto, R. Exploring TROP2 expression in oropharyngeal squamous cell carcinoma. Oral Oncology 169, 2025. e-Pub 2025. PMID: 40865331.
Even, C, Harrington, K, Massarelli, E, Laban, S, Fayette, J, Oliva, M, Klein Hesselink, M, Visscher, S, Fury, MG, Wiekmeijer, AS, Licitra, L, Melichar, B, Devriese, LA, Brana, I, Jankowska, P, Posner, MR, Glisson, BS, Kong, A, Hooftman, L, Melief, CJ, Ferrarotto, R. Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. Journal for immunotherapy of cancer 13(9), 2025. e-Pub 2025. PMID: 40921630.
Siqueira, JM, Mitani, Y, Marques-Piubelli, ML, Hoff, CO, Bonini, F, De Sousa, LG, Mitani, M, Carvalho, GL, Nunes, FD, De Matos, LL, Lin, S, Spiotto, MT, Hanna, EY, McGrail, DJ, El-Naggar, AK, Ferrarotto, R. TROP2 Expression in Salivary Gland Adenoid Cystic Carcinoma (ACC) According to Histologic Subtype. Journal of Oral Pathology and Medicine 54(8):658-666, 2025. e-Pub 2025. PMID: 40624990.
Kakouri, A, Debnam, M, Ferrarotto, R, Lu, T, Esmaeli, B. Successful Neoadjuvant Treatment Using Trastuzumab Emtansine (Kadcyla) for Locally Advanced and Metastatic Lacrimal Gland Adenocarcinoma. Ophthalmic plastic and reconstructive surgery 41(5):e183-e187, 2025. e-Pub 2025. PMID: 40334147.
Esmaeli B, Li Z, Lu TJ, Goldberg H, Ning J, Debnam JM, Frank SJ, Ferrarotto R. Disease-specific and overall survival for patients with lacrimal gland adenoid cystic carcinoma in recent decades. Br J Ophthalmol, 2025. e-Pub 2025. PMID: 40866108.
Jiang, XL, Rudqvist, N, Jiang, B, Ye, S, He, S, Liang, Q, Dou, J, Williams, MD, Dunn, J, Johnson, JM, Akagi, K, Xiao, W, Liang, S, Elayavalli, S, Sun, B, Parra Cuentas, ER, Ferrarotto, R, Garden, AS, Fuller, C, Reddy, JP, Gross, N, Lango, MN, Leung, CH, Liu, S, Liu, D, Li, M, Lee, JJ, Curran, M, Phan, J, Chen, K, Gillison, M. Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade. Cancer discovery 15(8):1569-1592, 2025. e-Pub 2025. PMID: 40249124.
Bell D, Choby G, Afkhami M, Maghami E, Ferrarotto R, Snyderman C, Wang E, Hanna E, Seethala R. Magnifying Glass on Sinonasal NUT Carcinoma Heterogeneity via Spatial Transcriptomics. Head Neck, 2025. e-Pub 2025. PMID: 40621801.
Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
Mitani, Y, Al-Maghrabi, H, Karpinets, T, Relator, R, Hilder, L, Chen, IY, Goepfert, RP, Bell, D, Zhang, J, Ferrarotto, R, El-Naggar, AK. Comparative transcriptomics of salivary basal cell adenoma and adenocarcinoma sustain linear neoplastic evolution and intertumor heterogeneity. Journal of Pathology 266(3):258-267, 2025. e-Pub 2025. PMID: 40272378.
Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann MC, Hosseini SM, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. J Clin Endocrinol Metab, 2025. e-Pub 2025. PMID: 40568752.
Hoff, CO, Feng, L, Bonini, F, Sousa, LG, Wang, K, Siqueira, JM, Nguyen, Q, El-Naggar, AK, Hofstetter, WL, Sepesi, B, Ferrarotto, R. Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma. Cancer 131(10), 2025. e-Pub 2025. PMID: 40377125.
Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
Hoff, CO, De Sousa, LG, Bonini, F, Lago, ED, Wang, K, Siqueira, JM, Mitani, Y, El-Naggar, AK, Ferrarotto, R. Clinical Outcomes With Notch Inhibitors in Notch-Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. Cancer medicine 14(5), 2025. e-Pub 2025. PMID: 40025676.
Tasoulas, J, Schrank, TP, Bharambe, H, Mehta, J, Johnson, S, Divaris, K, Hackman, TG, Sheth, S, Kirtane, KS, Hernandez, JC, Chung, CH, Yarbrough, WG, Ferrarotto, R, Issaeva, N, Theocharis, S, Amelio, AL. Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38982149.
Karpinets, T, Mitani, Y, Chang, C, Wu, X, Song, X, Flores, I, McDaniel, L, Hoballah, YM, Veguilla, FJ, Ferrarotto, R, Colbert, LE, Ajami, NJ, Jenq, RR, Zhang, J, Futreal, A, El-Naggar, AK. Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 39009605.
Brahimaj BC, Contrera KJ, Rubino F, Almeida RA, Ferrarotto R, Phan J, Su SY, Hanna EY, DeMonte F, Raza SM. Induction Chemotherapy for Sinonasal Tumors in Patients Presenting with Brain Invasion and/or Neurological Deficits. J Neurol Surg B Skull Base 85(6):650-658, 2024. e-Pub 2024. PMID: 39483161.
de Sousa LG, Ferrarotto R. B7-H4: A potential therapeutic target in adenoid cystic carcinoma. Oncotarget 15:807-808, 2024. e-Pub 2024. PMID: 39576662.
Contrera KJ, Ferrarotto R, Gunn B, Su SY, Kies MS, Glisson BS, Garden AS, Roberts D, Hanba C, Hoff CO, El-Naggar A, Williams MD, Raza SM, DeMonte F, Chen MM, Chambers MS, Hanna EY. Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res 31(2):258-265, 2024. e-Pub 2024. PMID: 39531535.
Bronk JK, Augustyn A, Mohamed ASR, David Fuller C, Garden AS, Moreno AC, Lee A, Morrison WH, Phan J, Reddy JP, Rosenthal DI, Spiotto MT, Frank SJ, Dadu R, Busaidy N, Zafereo M, Wang JR, Maniakas A, Ferrarotto R, Iyer PC, Cabanillas ME, Gunn GB. Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer. Radiother Oncol 202:110602, 2024. e-Pub 2024. PMID: 39489425.
de Moraes ATL, Dos Santos ES, Pedroso CM, Gomes RT, Ferrarotto R, Santos-Silva AR. Human oncogenic viruses: a focus on head and neck carcinogenesis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol 139(3):328-343, 2024. e-Pub 2024. PMID: 39551637.
Brahimaj, B, Contrera, KJ, Rubino, F, Almeida, RD, Ferrarotto, R, Phan, JL, Su, SY, Hanna, EY, DeMonte, F, Raza, SM. Induction Chemotherapy for Sinonasal Tumors in Patients Presenting with Brain Invasion and/or Neurological Deficits. Journal of Neurological Surgery, Part B: Skull Base 85(6):650-658, 2024. e-Pub 2024. PMID: 39483161.
Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
Zhao J, Williams MD, Hernandez M, Kuang G, Goldberg H, Fan J, Ning J, Ferrarotto R, Esmaeli B. Prognostic Impact of Notch1 Intracellular Domain, P63, and c-MYC in Lacrimal Gland Adenoid Cystic Carcinoma. Invest Ophthalmol Vis Sci 65(11):4, 2024. e-Pub 2024. PMID: 39230995.
Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn GB, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini SM, Busaidy NL, Cabanillas ME. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol 10(9):1264-1271, 2024. e-Pub 2024. PMID: 38990526.
Fan J, Goldberg H, Torres-Cabala CA, Stewart J, Nagarajan P, Debnam M, Crouse EC, Lu T, Ferrarotto R, Esmaeli B. Complete Response to Immunotherapy Using Pembrolizumab in a Patient With Conjunctival Squamous Cell Carcinoma With Nodal Metastasis. Ophthalmic Plast Reconstr Surg 40(5):e171-e174, 2024. e-Pub 2024. PMID: 38687306.
Goodman CD, DeMonte F, Nguyen TP, Garden AS, Wang CH, Wang XA, Diao K, Lee A, Reddy J, Moreno A, Spiotto M, Fuller CD, Rosenthal D, Ferrarotto R, Raza SM, Su SY, Warner A, Hanna E, Phan J. A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma. Head Neck 47(1):81-89, 2024. e-Pub 2024. PMID: 39073252.
Esmaeli B, Fan J, Goldberg H, Lu T, Gross ND, Akhave N, Sousa LG, Ferrarotto R. Immune checkpoint inhibitors with or without chemotherapy for orbital, conjunctival, and ocular adnexal squamous cell carcinoma. Can J Ophthalmol 60(1):e38-e51, 2024. e-Pub 2024. PMID: 39043259.
Hoff, CO, Manzi, J, Neto, FL, Ferrarotto, R. Vascular Endothelial Growth Factor Receptor Inhibitors for Recurrent or Metastatic Adenoid Cystic Carcinoma. JAMA Otolaryngology - Head and Neck Surgery 150(7):587-597, 2024. e-Pub 2024. PMID: 38814585.
Goldberg, H, Jiang, X, Fan, J, Zhao, J, Ning, J, Williams, MD, Frank, SJ, Moreno, AC, Gunn, GB, Ferrarotto, R, Esmaeli, B. Lacrimal Gland Adenocarcinoma Clinicopathologic Features and Outcomes Compared With Those of Lacrimal Gland Adenoid Cystic Carcinoma. Ophthalmic plastic and reconstructive surgery 40(4):419-425, 2024. e-Pub 2024. PMID: 38319188.
Hoff, CO, Dal Lago, EA, Siqueira, JM, De Sousa, LG, El-Naggar, AK, Rodon Ahnert, J, Ferrarotto, R. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38579194.
Dal Lago, EA, Guimares de Sousa, L, Yang, Z, Hoff, CO, Bonini, F, Sawyer, M, Wang, K, Lewis, WE, Wahid, K, Hanna, EY, El-Naggar, AK, Fuller, C, Kundu, S, Godoy, M, Ferrarotto, R. Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. Oral Oncology 151, 2024. e-Pub 2024. PMID: 38507991.
Goldfarb J, Fan J, de Sousa LG, Akhave N, Myers J, Goepfert R, Manisundaram K, Zhao J, Frank SJ, Moreno A, Ferrarotto R, Esmaeli B. Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas. Semin Ophthalmol:1-7, 2024. e-Pub 2024. PMID: 38500295.
Reyes-Gibby, CC, Qdaisat, AZ, Ferrarotto, R, Fadol, AP, Bischof, JJ, Coyne, CJ, Lipe, D, Hanna, EY, Shete, S, Abe, J, Yeung, SJ. Cardiovascular events after cancer immunotherapy as oncologic emergencies. Head and Neck 46(3):627-635, 2024. e-Pub 2024. PMID: 38151809.
Ferrarotto, R, Swiecicki, PL, Zandberg, DP, Baiocchi, R, Wesolowski, R, Rodriguez, CP, McKean, M, Kang, H, Monga, V, Nath, R, Palmisiano, N, Babbar, N, Sun, W, Hanna, GJ. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma. Oral Oncology 149, 2024. e-Pub 2024. PMID: 38118249.
Siqueira, JM, Mitani, Y, Hoff, CO, Bonini, F, Guimaraes de Sousa, L, Marques-Piubelli, ML, Purushothaman, A, Mitani, M, Dai, H, Lin, SY, Spiotto, MT, Hanna, EY, McGrail, DJ, El-Naggar, AK, Ferrarotto, R. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma–Specific Prognostic Relevance. Modern Pathology 37(1), 2024. e-Pub 2024. PMID: 38015043.
Ramesh, U, Contrera, KJ, Shakibai, N, Su, SY, Brahimaj, B, Roberts, DB, Williams, MD, Ferrarotto, R, Phan, J, Gunn, GB, Raza, SM, DeMonte, F, Hanna, EY. Sinonasal NUT carcinoma. Head and Neck 46(1):29-36, 2024. e-Pub 2024. PMID: 37853958.
Zhao Z, Frank SJ, Ning J, Zhao J, Jiang X, Wang XA, Schefler AC, Hanna E, Moreno A, Gunn B, Ferrarotto R, Esmaeli B. Visual outcome and ocular complications in patients with lacrimal gland carcinoma after eye-sparing surgery and adjuvant radiation therapy. Br J Ophthalmol 107(12):1914-1919, 2023. e-Pub 2022. PMID: 36229179.
Bonini F, de Sousa LG, Ferrarotto R. New and emerging drugs for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Emerg Drugs 28(2):97-106, 2023. e-Pub 2023. PMID: 37144289.
Gross, N, Miller, DM, Khushalani, N, Divi, V, Ruiz, E, Lipson, EJ, Meier, F, Su, YB, Swiecicki, PL, Atlas, J, Geiger, JL, Hauschild, A, Choe, J, Hughes, BG, Schadendorf, D, Patel, VA, Homsi, J, Taube, JM, Lim, AM, Ferrarotto, R, Yoo, SY, Mathias, M, Han, H, Seebach, F, Lowy, I, Fury, MG, Rischin, D. Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma. The lancet oncology 24(11):1196-1205, 2023. e-Pub 2023. PMID: 37875144.
Persson M, Andersson MK, Sahlin PE, Mitani Y, Brandwein-Weber MS, Frierson HF, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol 261(3):256-268, 2023. e-Pub 2023. PMID: 37565350.
Caruso G, Ferrarotto R, Curcio A, Metro L, Pasqualetti F, Gaviani P, Barresi V, Angileri FF, Caffo M. Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications. Cancers (Basel) 15(18), 2023. e-Pub 2023. PMID: 37760490.
Ferrarotto R, Nagarajan P, Maronge JM, Johnson JM, Rosenthal DI, Myers JN, Gross ND. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. JAMA Otolaryngol Head Neck Surg 149(9):847-849, 2023. e-Pub 2023. PMID: 37535378.
Sousa LG, McGrail DJ, Lazar Neto F, Li K, Marques-Piubelli ML, Ferri-Borgogno S, Dai H, Mitani Y, Spardy Burr N, Cooper ZA, Kinneer K, Cortez MA, Lin SY, Bell D, El Naggar A, Burks J, Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res 29(16):3162-3171, 2023. e-Pub 2023. PMID: 37256648.
Contrera KJ, Shakibai N, Su SY, Gule-Monroe MK, Roberts D, Brahimaj B, Williams MD, Ferrarotto R, Phan J, Gunn B, Raza S, DeMonte F, Hanna EY. Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. Otolaryngol Head Neck Surg 169(2):435-440, 2023. e-Pub 2023. PMID: 36856048.
Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK. Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res 29(14):2737, 2023. e-Pub 2023. PMID: 37449360.
Amit M, Baruch E, Nagarajan P, Gleber-Netto F, Rao X, Xie T, Akhter S, Adewale A, Islam S, Mattson B, Ferrarotto R, Wong M, Davies M, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunarante P, Goepfert R, Khushalani N, Wang J, Watowich S, Calin G, Migden M, Vermeer P, D'Silva N, Yaniv D, Burks J, Gomez J, Dougherty P, Tsai K, Allison J, Sharma P, Wargo J, Myers J, Gross N. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
Zhang X, Gleber-Netto FO, Wang S, Jin KW, Yang DM, Gillenwater AM, Myers JN, Ferrarotto R, Pickering CR, Xiao G. A Deep Learning Onion Peeling Approach to Measure Oral Epithelium Layer Number. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568707.
Bahig H, Ehab HY, Garden AS, Ng SP, Frank SJ, Nguyen T, Gunn GB, Rosenthal DI, Fuller CD, Ferrarotto R, Bell D, Su S, Phan J. Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience. Head Neck 45(7):1692-1703, 2023. e-Pub 2023. PMID: 37165701.
Wotman M, El-Naggar A, Ferrarotto R. Targeting human EGFR 2 (HER2) in salivary gland carcinoma. Expert Rev Anticancer Ther 23(6):573-582, 2023. e-Pub 2023. PMID: 37114470.
Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol 41(15):2843-2851, 2023. e-Pub 2023. PMID: 36898078.
Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study. Thyroid 33(4):484-491, 2023. e-Pub 2023. PMID: 36762947.
Goldfarb JA, Ferrarotto R, Gross N, Goepfert R, Debnam JM, Gunn B, Nagarajan P, Esmaeli B. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol 107(3):320-323, 2023. e-Pub 2021. PMID: 34625433.
William WN, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer 129(5):714-727, 2023. e-Pub 2023. PMID: 36597662.
de Sousa LG, Lazar Neto F, Dal Lago EA, Sikora A, Hanna E, Moreno A, Phan J, Glisson BS, Bell D, Ferrarotto R. Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma. Oral Oncol 138:106311, 2023. e-Pub 2023. PMID: 36702015.
Zhang X, Gleber-Netto FO, Wang S, Martins-Chaves RR, Gomez RS, Vigneswaran N, Sarkar A, William WN, Papadimitrakopoulou V, Williams M, Bell D, Palsgrove D, Bishop J, Heymach JV, Gillenwater AM, Myers JN, Ferrarotto R, Lippman SM, Pickering CR, Xiao G. Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. Cancer Med 12(6):7508-7518, 2023. e-Pub 2023. PMID: 36721313.
Zhao J, Jiang X, Hanna E, Su SY, Moreno A, Gunn B, Frank SJ, Ferrarotto R, Ning J, Esmaeli B. Orbital and periocular complications in patients with sinonasal tumours with orbital invasion. Br J Ophthalmol 108(3):465-470, 2023. e-Pub 2023. PMID: 36707226.
Weissferdt A, Sepesi B, Ning J, Hermsen M, Ferrarotto R, Glisson B, Hanna E, Bell D. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep 25(1):1-10, 2023. e-Pub 2022. PMID: 36422794.
Wagner VP, Ferrarotto R, Vargas PA, Martins MD, Bingle CD, Bingle L. Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials. Crit Rev Oncol Hematol 181:103886, 2023. e-Pub 2023. PMID: 36427771.
Locati LD, Ferrarotto R, Licitra L, Benazzo M, Preda L, Farina D, Gatta G, Lombardi D, Nicolai P, Vander Poorten V, Chua MLK, Vischioni B, Sanguineti G, Morbini P, Fonseca I, Sozzi D, Merlotti A, Orlandi E. Current management and future challenges in salivary glands cancer. Front Oncol 13:1264287, 2023. e-Pub 2023. PMID: 37795454.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Validation of cancer-type dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol 33(11):1204-1206, 2022. e-Pub 2022. PMID: 35926816.
Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N Engl J Med 387(17):1557-1568, 2022. e-Pub 2022. PMID: 36094839.
Wang JR, Montierth M, Xu L, Goswami M, Zhao X, Cote G, Wang W, Iyer P, Dadu R, Busaidy NL, Lai SY, Gross ND, Ferrarotto R, Lu C, Gunn GB, Williams MD, Routbort M, Zafereo ME, Cabanillas ME. Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma. JCO Precis Oncol 6:e2100504, 2022. e-Pub 2022. PMID: 35977347.
Taku N, Chronowski G, Brandon Gunn G, Morrison WH, Gross ND, Moreno AC, Ferrarotto R, Frank SJ, Fuller CD, Goepfert RP, Phan J, Lai SY, Reddy JP, Rosenthal DI, Garden AS. Unilateral Radiation Therapy for Tonsillar Cancer: Treatment Outcomes in the Era of Human Papillomavirus, Positron-Emission Tomography, and Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 113(5):1054-1062, 2022. e-Pub 2022. PMID: 35504500.
Lazar Neto F, Sousa LG, Lewis WE, Glisson B, Heymach JV, Tsao AS, Ferrarotto R. Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med 37(8):8850666211061312, 2022. e-Pub 2022. PMID: 34787022.
de Sousa LG, Jovanovic K, Ferrarotto R. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments. Curr Treat Options Oncol 23(8):1135-1150, 2022. e-Pub 2022. PMID: 35854180.
Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Davis M, Kaye J, Weber CR, Shen L, Pearson AT, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis 13(8):678, 2022. e-Pub 2022. PMID: 35931701.
Persson M, Andersson MK, Mitani Y, Brandwein-Weber MS, Frierson HF, Moskaluk C, Fonseca I, Ferrarotto R, Boecker W, Loening T, El-Naggar AK, Stenman G. Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35954356.
López F, Shah JP, Beitler JJ, Snyderman CH, Lund V, Piazza C, Mäkitie AA, Guntinas-Lichius O, Rodrigo JP, Kowalski LP, Quer M, Shaha A, Homma A, Sanabria A, Ferrarotto R, Lee AWM, Lee VHF, Rinaldo A, Ferlito A. The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours. Adv Ther 39(6):2379-2397, 2022. e-Pub 2022. PMID: 35352310.
de Sousa LG, Neto FL, Lin J, Ferrarotto R. Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma. Curr Oncol Rep 24(5):621-631, 2022. e-Pub 2022. PMID: 35212920.
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 28(8):1735, 2022. e-Pub 2022. PMID: 35419587.
Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer 10(3), 2022. e-Pub 2022. PMID: 35241495.
Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, Lewis WE, Rivera MJ, Kaya D, El-Naggar AK, Hanna EY, Esmaeli B, Frank SJ, Bell D, Glisson BS, Rodon J, Meric-Bernstam F, Lee JJ, Ferrarotto R. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer 128(3):509-518, 2022. e-Pub 2022. PMID: 34661906.
Abdelmeguid AS, Bell D, Roberts D, Ferrarotto R, Phan J, Su SY, Kupferman M, Raza S, DeMonte F, Hanna E. Long-Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature. Laryngoscope 132(2):290-297, 2022. e-Pub 2022. PMID: 34272876.
Sousa LG, Rajapakshe K, Rodriguez Canales J, Chin RL, Feng L, Wang Q, Barrese TZ, Massarelli E, William W, Johnson FM, Ferrarotto R, Wistuba I, Coarfa C, Lee J, Wang J, Melief CJM, Curran MA, Glisson BS. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35193933.
Amit M, Liu C, Mansour J, Gleber-Netto FO, Tam S, Baruch EN, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Tsai K, Flores ER, Migden MR, Silverman DA, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 127(23):4413-4420, 2021. e-Pub 2021. PMID: 34358340.
de Sousa LG, Ferrarotto R. Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Rev Anticancer Ther 21(12):1321-1331, 2021. e-Pub 2021. PMID: 34689660.
Sousa LG, Lazar Neto F, Torman DK, Diaz EM, Rosenthal DI, Glisson BS, Bell D, Ferrarotto R. Therapeutic approaches and outcomes in patients with larynx or hypopharynx high-grade neuroendocrine carcinoma: A single-center retrospective analysis. Head Neck 43(12):3788-3795, 2021. e-Pub 2021. PMID: 34524729.
Diao K, Nguyen TP, Moreno AC, Reddy JP, Garden AS, Wang CH, Tung S, Wang C, Wang XA, Rosenthal DI, Fuller CD, Gunn GB, Frank SJ, Morrison WH, Shah SJ, Lee A, Spiotto MT, Su SY, Ferrarotto R, Phan J. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: A large, single-institution, modern cohort study. Head Neck 43(11):3331-3344, 2021. e-Pub 2021. PMID: 34269492.
Kiong KL, Bell D, Yao CM, Ferrarotto R, Lewis CM. Multifocal regression and pathologic response predicts recurrence after neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Oral Oncol 122:105520, 2021. e-Pub 2021. PMID: 34521029.
Ferrarotto R, Anderson I, Medgyasszay B, García-Campelo MR, Edenfield W, Feinstein TM, Johnson JM, Kalmadi S, Lammers PE, Sanchez-Hernandez A, Pritchett Y, Morris SR, Malik RK, Csoszi T. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Med 10(17):5748-5756, 2021. e-Pub 2021. PMID: 34405547.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Ann Oncol 32(9):1194-1197, 2021. e-Pub 2021. PMID: 34166757.
Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
Abdelmeguid AS, Silver NL, Boonsripitayanon M, Glisson BS, Ferrarotto R, Gunn GB, Phan J, Gillenwater AM, Hanna EY. Role of induction chemotherapy for oral cavity squamous cell carcinoma. Cancer 127(17):3107-3112, 2021. e-Pub 2021. PMID: 33909292.
Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME. Clinical Utility of Circulating Cell-free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid 31(8):1235-1243, 2021. e-Pub 2021. PMID: 33599171.
Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther 38(8):4581-4591, 2021. e-Pub 2021. PMID: 34241781.
Guo TW, Saiyed F, CMKL Y, Kiong KL, Martinez J, Sacks R, Lee JJ, Moreno AC, Frank SJ, Rosenthal DI, Glisson BS, Ferrarotto R, Mott FE, Johnson FM, Myers JN. Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer 127(16):2916-2925, 2021. e-Pub 2021. PMID: 33873251.
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
Karpinets TV, Mitani Y, Liu B, Zhang J, Pytynia KB, Sellen LD, Karagiannis DT, Ferrarotto R, Futreal AP, El-Naggar AK. Whole-genome Sequencing of Common Salivary Gland Carcinomas: Subtype Restricted and Shared Genetic Alterations. Clin Cancer Res 27(14):3960-3969, 2021. e-Pub 2021. PMID: 34011559.
van Dijk LV, Mohamed ASR, Ferrarotto R, McCoy LA, Sharafi CS, Jones E, Steele K, Moreno AC, Lai SY, Garden AS, Myers JN, Rosenthal DI, Fuller CD, Hutcheson KA, MD Anderson Symptom Working Group MD. The impact of induction and/or concurrent chemoradiotherapy on acute and late patient-reported symptoms in oropharyngeal cancer: Application of a mixed-model analysis of a prospective observational cohort registry. Cancer 127(14):2453-2464, 2021. e-Pub 2021. PMID: 33788956.
Abdelmeguid, AS, Teeramatwanich, W, Roberts, DB, Amit, M, Ferrarotto, R, Glisson, BS, Kupferman, ME, Su, SY, Phan, J, Garden, AS, Raza, SM, DeMonte, F, Hanna, EY. Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer 127(11):1788-1795, 2021. e-Pub 2021. PMID: 33567468.
Taku N, Wang L, Garden AS, Rosenthal DI, Gunn GB, Morrison WH, Fuller CD, Phan J, Reddy JP, Moreno AC, Spiotto MT, Chronowski G, Shah SJ, Mayo LL, Gross ND, Ferrarotto R, Zhu XR, Zhang X, Frank SJ. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy. Curr Treat Options Oncol 22(6):54, 2021. e-Pub 2021. PMID: 34086150.
Ford JR, Rubin ML, Frank SJ, Ning J, Debnam JM, Bell D, El-Naggar A, Ferrarotto R, Esmaeli B. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol 105(6):768-774, 2021. e-Pub 2021. PMID: 32680839.
Kiong KL, CMKL Y, Lin FY, Bell D, Ferrarotto R, Weber RS, Lewis CM. Delay to surgery after neoadjuvant chemotherapy in head and neck squamous cell carcinoma affects oncologic outcomes. Cancer 127(12):1984-1992, 2021. e-Pub 2021. PMID: 33631040.
Choi KY, Amit M, Tam S, Bell D, Phan J, Garden AS, Williams MD, Ferrarotto R, El-Naggar AK, Raza SM, DeMonte F, Kupferman ME, Hanna EY, Su SY. Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope 131(5):E1468-E1475, 2021. e-Pub 2021. PMID: 32946597.
Aggarwal P, Goepfert RP, Garden AS, Garg N, Zaveri JS, Du XL, Swartz MD, Lai SY, Fuller CD, Ferrarotto R, Sturgis EM, Piller LB, Hutcheson KA. Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngol Head Neck Surg 147(5):469-478, 2021. e-Pub 2021. PMID: 33538759.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32(5):661-672, 2021. e-Pub 2021. PMID: 33736924.
Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
Dahlstrom KR, Song J, Thall PF, Fuller CD, Hutcheson KA, Johnson FM, Gunn GB, Phan J, Frank SJ, Morrison WH, Ferrarotto R, Rosenthal DI, Sturgis EM, Garden AS. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer 127(8):1228-1237, 2021. e-Pub 2021. PMID: 33306202.
Schvartsman G, Bell D, Rubin ML, Tetzlaff M, Hanna E, Lee JJ, Weber R, Phan J, Glisson BS, Ferrarotto R. The tumor immune contexture of salivary duct carcinoma. Head Neck 43(4):1213-1219, 2021. e-Pub 2021. PMID: 33576119.
Amit M, Liu C, Gleber-Netto FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Baruch EN, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer 127(8):1238-1245, 2021. e-Pub 2021. PMID: 33320343.
Huang, C, Chen, L, Savage, SR, Eguez, RV, Dou, Y, Li, Y, da Veiga Leprevost, F, Jaehnig, EJ, Lei, JT, Wen, B, Schnaubelt, M, Krug, K, Song, X, Cieślik, M, Chang, HY, Wyczalkowski, MA, Li, K, Colaprico, A, Li, QK, Clark, DJ, Hu, Y, Cao, L, Pan, J, Wang, Y, Cho, KC, Shi, Z, Liao, Y, Jiang, W, Anurag, M, Ji, J, Yoo, S, Zhou, DC, Liang, WW, Wendl, MC, Vats, P, Carr, SA, Mani, DR, Zhang, Z, Qian, J, Chen, X, Pico, AR, Wang, P, Chinnaiyan, AM, Ketchum, KA, Kinsinger, C, Robles, AI, An, E, Sikora, AG, El-Naggar, AK, Ferrarotto, R. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer cell 39(3):361-379.e16, 2021. e-Pub 2021. PMID: 33417831.
Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res 27(3):852-864, 2021. e-Pub 2021. PMID: 33172898.
Liu W, Qdaisat A, Zhou S, Fuller CD, Ferrarotto R, Guo M, Lai SY, Cardoso R, Mohamed ASR, Lopez G, Narayanan S, van Dijk LV, Cohen L, Bruera E, Yeung SJ, Hanna EY. Hypomagnesemia and incidence of osteoradionecrosis in patients with head and neck cancers. Head Neck 43(2):613-621, 2021. e-Pub 2021. PMID: 33094893.
Amit M, Liu C, Netto Gleber FO, Kini S, Tam S, Benov A, Aashiq M, El-Naggar AK, Moreno AC, Rosenthal DI, Glisson BS, Ferrarotto R, Wong MK, Migden MR, Li G, Khanna A, Goepfert RP, Nagarajan P, Weber RS, Myers JN, Gross ND. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer 144:169-177, 2021. e-Pub 2021. PMID: 33352413.
Ng SP, Bahig H, Jethanandani A, Sturgis EM, Johnson FM, Elgohari B, Gunn GB, Ferrarotto R, Phan J, Rosenthal DI, Frank SJ, Fuller CD, Garden AS. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. Br J Cancer 124(3):628-633, 2021. e-Pub 2021. PMID: 33051590.
Christopherson KM, Moreno AC, Elgohari B, Gross N, Ferrarotto R, Mohamed ASR, Brandon Gunn G, Goepfert RP, Mott FE, Shah SJ, David Fuller C, Reddy JP, Frank SJ, Morrison WH, Phan J, Rosenthal DI, Garden AS. Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol 113:105125, 2021. e-Pub 2021. PMID: 33360375.
Liu W, Qdaisat A, Ferrarotto R, Fuller CD, Guo M, Meyer LA, Narayanan S, Lopez G, Cohen L, Bruera E, Hanna EY, Yeung SJ. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation. Cancer 127(4):528-534, 2021. e-Pub 2021. PMID: 33085092.
Hart LL, R F, Andric ZG, Beck JT, Subramanian J, Radosavljevic DZ, Zaric B, Hanna WT, Aljumaily R, Owonikoko TK, Verhoeven D, Xiao J, Morris SR, Antal JM, Hussein MA. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Adv Ther 38(1):350-365, 2021. e-Pub 2021. PMID: 33123968.
Di Villeneuve L, Souza IL, Tolentino FDS, Ferrarotto R Schvartsman G. Corrigendum: Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front Oncol 11:669486, 2021. e-Pub 2021. PMID: 33898325.
Gunn GB, Garden AS, Ye R, Ausat N, Dahlstrom KR, Morrison WH, Fuller CD, Phan J, Reddy JP, Shah SJ, Mayo LL, Chun SG, Chronowski GM, Moreno AC, Myers JN, Hanna EY, Esmaeli B, Gillison ML, Ferrarotto R, Hutcheson KA, Chambers MS, Ginsberg LE, El-Naggar AK, Rosenthal DI, Zhu XR, Frank SJ. Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther 8(1):108-118, 2021. e-Pub 2021. PMID: 34285940.
Bahig H, Gunn BG, Garden AS, Ye R, Hutcheson K, Rosenthal DI, Phan J, Fuller CD, Morrison WH, Reddy JP, Ng SP, Gross ND, Sturgis EM, Ferrarotto R, Gillison M, Frank SJ. Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. Int J Part Ther 8(1):213-222, 2021. e-Pub 2021. PMID: 34285948.
Sherry AD, Pasalic D, Gunn GB, Fuller CD, Phan J, Rosenthal DI, Morrison WH, Sturgis EM, Gross ND, Gillison ML, Ferrarotto R, El-Naggar AK, Garden AS, Frank SJ. Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther 8(1):234-247, 2021. e-Pub 2021. PMID: 34285950.
Hanania AN, Zhang X, Gunn GB, Rosenthal DI, Garden AS, Fuller CD, Phan J, Reddy JP, Moreno A, Chronowski G, Shah S, Ausat N, Hanna E, Ferrarotto R, Frank SJ. Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes. Int J Part Ther 8(1):261-272, 2021. e-Pub 2021. PMID: 34285952.
Bell D, Bell A, Ferrarotto R, Glisson B, Takahashi Y, Fuller G, Weber R, Hanna E. High-grade sinonasal carcinomas and surveillance of differential expression in immune related transcriptome. Ann Diagn Pathol 49:151622, 2020. e-Pub 2020. PMID: 32927372.
Hamza A, R F, Kaya D, Weber RS, Bell D. von Ebner's glands intercalated duct adenocarcinoma with PALB2 gene mutation. Ann Diagn Pathol 49:151637, 2020. e-Pub 2020. PMID: 33069082.
Ng SP, Wang H, Pollard C, Nguyen T, Bahig H, Fuller CD, Gunn GB, Garden AS, Reddy JP, Morrison WH, Shah S, Rosenthal DI, Frank SJ, Guha-Thakurta N, Ferrarotto R, Hanna EY, Su SY, Phan J. Patient Outcomes after Reirradiation of Small Skull Base Tumors using Stereotactic Body Radiotherapy, Intensity Modulated Radiotherapy, or Proton Therapy. J Neurol Surg B Skull Base 81(6):638-644, 2020. e-Pub 2020. PMID: 33381367.
Bagley AF, Garden AS, Reddy JP, Moreno AC, Frank SJ, Rosenthal DI, Morrison WH, Gunn GB, Fuller CD, Shah SJ, Ferrarotto R, Sturgis EM, Gross ND, Phan J. Highly conformal reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head Neck 42(11):3326-3335, 2020. e-Pub 2020. PMID: 32776401.
Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist 25(10):e1457-e1463, 2020. e-Pub 2020. PMID: 32608142.
Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33106386.
Kiong KL, Lin FY, CMKL Y, Guo T, Ferrarotto R, Weber RS, Lewis CM. Impact of neoadjuvant chemotherapy on perioperative morbidity after major surgery for head and neck cancer. Cancer 126(19):4304-4314, 2020. e-Pub 2020. PMID: 32706401.
Stieb S, Perez-Martinez I, Mohamed ASR, Rock S, Bajaj N, Deshpande TS, Zaid M, Garden AS, Goepfert RP, Cardoso R, Ferrarotto R, Reddy JP, Phan J, Morrison WH, Rosenthal DI, Koay EJ, Frank SJ, Fuller CD, Gunn GB, MD Anderson Head MD, Working Group NCS. The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors. Clin Transl Radiat Oncol 24:71-78, 2020. e-Pub 2020. PMID: 32642562.
Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, Williams MD, Gunn GB, Hofmann MC, Cote G, Sperling J, Gross ND, Sturgis EM, Goepfert RP, Lai SY, Cabanillas ME, Zafereo M. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncol 6(9):1397-1404, 2020. e-Pub 2020. PMID: 32761153.
Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, Phan J, Cardenas C, Ferrarotto R, Frank SJ, Rosenthal DI, Garden AS. Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. Adv Radiat Oncol 5(5):929-935, 2020. e-Pub 2020. PMID: 33083655.
Garden AS, Kamal M, Mohamed ASR, Frank SJ, Lewin JS, Lai SY, Morrison WH, Phan J, Ferrarotto R, Rosenthal DI, Hutcheson KA, Fuller CD, Gunn GB. Neurologic sequelae following radiation with and without chemotherapy for oropharyngeal cancer: Patient reported outcomes study. Head Neck 42(8):2137-2144, 2020. e-Pub 2020. PMID: 32212359.
Lee DY, Brayer KJ, Mitani Y, Burns EA, Rao PH, Bell D, Williams MD, Ferrarotto R, Pytynia KB, El-Naggar AK, Ness SA. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel) 12(9), 2020. e-Pub 2020. PMID: 32867110.
Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, Phan J, Elamin YY, Torman DK, Warneke CL, Hessel AC, Garden AS, Myers JN, Johnson FM, Lee JJ, Sikora AG, Gillison ML, Glisson BS, Gross ND. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial. Clin Cancer Res 26(13):3211-3219, 2020. e-Pub 2020. PMID: 32269052.
Le X, Ferrarotto R, Wise-Draper T, Gillison M. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer. J Natl Compr Canc Netw 18(7):899-906, 2020. e-Pub 2020. PMID: 32634775.
Grant SR, Hutcheson KA, Ye R, Garden AS, Morrison WH, Rosenthal DI, Brandon Gunn G, Fuller CD, Phan J, Reddy JP, Moreno AC, Lewin JS, Sturgis EM, Ferrarotto R, Frank SJ. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol 148:133-139, 2020. e-Pub 2020. PMID: 32361662.
Pasalic D, Ludmir EB, Allen PK, Thaker NG, Chapman BV, Hanna EY, Su SY, Ferrarotto R, Glisson BS, Reddy JP, Brandon Gunn G, Fuller CD, Phan J, Rosenthal DI, Morrison WH, Garden AS, Frank SJ. Patient-Reported Outcomes, Physician-Reported Toxicities, and Treatment Outcomes in a Modern Cohort of Patients with Sinonasal Cancer Treated Using Proton Beam Therapy. Radiother Oncol 148:258-266, 2020. e-Pub 2020. PMID: 32417351.
Saluja K, Ravishankar S, Ferrarotto R, Zhu H, Pytynia KB, El-Naggar AK. Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications. Head Neck Pathol 14(2):562-569, 2020. e-Pub 2020. PMID: 31363907.
Kiong KL, Guo T, CMKL Y, Gross ND, Hanasono MM, Ferrarotto R, Rosenthal DI, Myers JN, Hanna EY, Lai SY. Changing practice patterns in head and neck oncologic surgery in the early COVID-19 era. Head Neck 42(6):1179-1186, 2020. e-Pub 2020. PMID: 32459061.
MD Anderson Head MD, Guidelines Consortium NST, members C, Maniakas A, Jozaghi Y, Zafereo ME, Sturgis EM, Su SY, Gillenwater AM, Gidley PW, Lewis CM, Diaz E, Goepfert RP, Kupferman ME, Gross ND, Hessel AC, Pytynia KB, Nader ME, Wang JR, Lango MN, Kiong KL, Guo T, Zhao X, CMKL Y, Appelbaum E, Alpard J, Garcia JA, Terry S, Flynn JE, Bauer S, Fournier D, Burgess CG, Wideman C, Johnston M, You C, De Luna R, Joseph L, Diersing J, Prescott K, Heiberger K, Mugartegui L, Rodriguez J, Zendehdel S, Sellers J, Friddell RA, Thomas A, Khanjae SJ, Schwarzlose KB, Chambers MS, Hofstede TM, Cardoso RC, Wesson RA, Won A, Otun AO, Gombos DS, Al-Zubidi N, Hutcheson KA, Gunn GB, Rosenthal DI, Gillison ML, Ferrarotto R, Weber RS, Hanna EY, Myers JN, Lai SY. Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the COVID-19 pandemic. Head Neck 42(6):1194-1201, 2020. e-Pub 2020. PMID: 32342541.
Stieb S, Mohamed ASR, Deshpande TS, Harp J, Greiner B, Garden AS, Goepfert RP, Cardoso R, Ferrarotto R, Phan J, Reddy JP, Morrison WH, Rosenthal DI, Frank SJ, Fuller CD, Brandon Gunn G, MD Anderson Head MD, Working Group NCS. Prospective observational evaluation of radiation-induced late taste impairment kinetics in oropharyngeal cancer patients: Potential for improvement over time?. Clin Transl Radiat Oncol 22:98-105, 2020. e-Pub 2020. PMID: 32373720.
Choi JS, Sansoni ER, Lovin BD, Lindquist NR, Phan J, Mayo LL, Ferrarotto R, Su SY. Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. Ann Otol Rhinol Laryngol 129(5):3489419896602, 2020. e-Pub 2020. PMID: 31875405.
Ng SP, Cardenas CE, Elhalawani H, Pollard C 3rd, Elgohari B, Fang P, Meheissen M, Guha-Thakurta N, Bahig H, Johnson JM, Kamal M, Garden AS, Reddy JP, Su SY, Ferrarotto R, Frank SJ, Brandon Gunn G, Moreno AC, Rosenthal DI, Fuller CD, Phan J. Comparison of tumor delineation using dual energy computed tomography versus magnetic resonance imaging in head and neck cancer re-irradiation cases. Phys Imaging Radiat Oncol 14:1-5, 2020. e-Pub 2020. PMID: 33458306.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
Mitani Y, Lin SH, Pytynia KB, Ferrarotto R, El-Naggar AK. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res 26(5):1175-1184, 2020. e-Pub 2020. PMID: 31772120.
Bahig H, Ng SP, Pollard C, Nguyen TP, Gunn GB, Rosenthal DI, Fuller CD, Frank SJ, Garden AS, Reddy JP, Morrison WH, Ferrarotto R, Hanna EY, DeMonte F, Su SY, Phan J. A prospective evaluation of health-related quality of life after skull base re-irradiation. Head Neck 42(3):485-497, 2020. e-Pub 2020. PMID: 31868271.
Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting. Oral Oncol 102:104440, 2020. e-Pub 2020. PMID: 31648864.
Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch 476(2):295-305, 2020. e-Pub 2020. PMID: 31423558.
Pestana RC, Becnel M, Rubin ML, Torman DK, Crespo J, Phan J, Hanna E, Bell D, Glisson BS, Johnson JM, Lee JJ, Ferrarotto R. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 101:104523, 2020. e-Pub 2020. PMID: 31864957.
Tam S, Yao CMK, Amit M, Gajera M, Luo X, Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, El-Naggar A, Migden M, Wong M, Glisson B, Ferrarotto R, Esmaeli B, Rosenthal D, Li G, Weber RS, Myers JN, Gross ND. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg 146(2):128-135, 2020. e-Pub 2020. PMID: 31804658.
Bagley AF, Ye R, Garden AS, Gunn GB, Rosenthal DI, Fuller CD, Morrison WH, Phan J, Sturgis EM, Ferrarotto R, Wu R, Liu AY, Frank SJ. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol 142:133-139, 2020. e-Pub 2020. PMID: 31431373.
Tyler MA, Mohamed ASR, Smith JB, Aymard JM, Fuller CD, Phan J, Frank SJ, Ferrarotto R, Kupferman ME, Hanna EY, Gunn GB, Su SY. Long-term quality of life after definitive treatment of sinonasal and nasopharyngeal malignancies. Laryngoscope 130(1):86-93, 2020. e-Pub 2020. PMID: 30706478.
Hutcheson KA, Warneke CL, CMKL Y, Zaveri J, Elgohari BE, Goepfert R, Hessel AC, Kupferman ME, Lai SY, Fuller CD, Gunn GB, Garden AS, Johnson F, Ferrarotto R, Lewin JS, Gross ND, MD Anderson Head MD, Working Group NCS. Dysphagia After Primary Transoral Robotic Surgery With Neck Dissection vs Nonsurgical Therapy in Patients With Low- to Intermediate-Risk Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. e-Pub 2019. PMID: 31556933.
Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 7(1):237, 2019. e-Pub 2019. PMID: 31484556.
Bell AH, Prieto VG, Ferrarotto R, Goepfert RP, Myers JN, Weber R, Bell D. Magnifying glass on spiradenoma and cylindroma histogenesis and tumorigenesis using systematic transcriptome analysis. Ann Diagn Pathol 41:14-23, 2019. e-Pub 2019. PMID: 31128548.
Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036-1043, 2019. e-Pub 2019. PMID: 31319771.
Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, Elamin Y, Thakar SD, Nagarajan P, Esmaeli B. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg 35(4):350-353, 2019. e-Pub 2019. PMID: 30365473.
Hamza A, Roberts D, Su S, Weber RS, Bell D, Ferrarotto R. PD-L1 expression by immunohistochemistry in salivary duct carcinoma. Ann Diagn Pathol 40:49-52, 2019. e-Pub 2019. PMID: 30978575.
Ng SP, Pollard C, Berends J, Ayoub Z, Kamal M, Garden AS, Bahig H, Cantor SB, Schaefer AJ, Ajayi T, Gunn GB, Frank SJ, Skinner H, Phan J, Morrison WH, Ferrarotto R, Johnson JM, Mohamed ASR, Lai SY, Hessel AC, Sturgis EM, Weber RS, Fuller CD, Rosenthal DI. Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. Cancer 125(11):1823-1829, 2019. e-Pub 2019. PMID: 30748005.
Sagiv O, Nagarajan P, Ferrarotto R, Kandl TJ, Thakar SD, Glisson BS, Altan M, Esmaeli B. Ocular Preservation with Neoadjuvant Vismodegib in Patients with Locally Advanced Periocular Basal Cell Carcinoma. Br J Ophthalmol 103(6):775-780, 2019. e-Pub 2019. PMID: 30021814.
Ibrahim MY, Nunez MI, Harun N, Lee JJ, El-Naggar AK, Ferrarotto R, Wistuba I, Myers J, Glisson BS, William WN. PI3-kinase Pathway Biomarkers in Oral Cancer and Tumor Immune Cells. Head Neck 41(3):615-622, 2019. e-Pub 2019. PMID: 30556200.
Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, Ferrarotto R, Glisson B, Kupferman ME, Roberts DB, Su SY, Raza SM, DeMonte F, Hanna EY. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol 37(6):JCO1800353, 2019. e-Pub 2019. PMID: 30615549.
Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5(1):67-73, 2019. e-Pub 2019. PMID: 30267032.
Ng SP, Pollard C, Kamal M, Ayoub Z, Garden AS, Bahig H, Gunn GB, Frank SJ, Skinner HD, Phan J, Berends J, Morrison WH, Johnson JM, Ferrarotto R, Sturgis EM, Mohamed ASR, Lai SY, Fuller CD, Rosenthal DI. Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. NPJ Precis Oncol 3:22, 2019. e-Pub 2019. PMID: 31583278.
Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BG, Skinner HD, Garden AS, Cabanillas ME. Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol 2, 2018. e-Pub 2018. PMID: 35135166.
Mays AC, Hanna EY, Ferrarotto R, Phan J, Bell D, Silver N, Mulcahy CF, Roberts D, Abdelmeguid ASA, Fuller CD, Frank SJ, Raza SM, Kupferman ME, DeMonte F, Su SY. Prognostic Factors and Survival in Adenoid Cystic Carcinoma of the Sinonasal Cavity. Head Neck 40(12):2596-2605, 2018. e-Pub 2018. PMID: 30447126.
Working Group MLC, Mulcahy CF, Mohamed ASR, Kanwar A, Hutcheson KA, Ghosh A, Vock D, Weber RS, Lai SY, Gunn GB, Zafereo M, Morrison WH, Ferrarotto R, Garden AS, Rosenthal DI, Fuller CD. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck 40(9):2060-2069, 2018. e-Pub 2018. PMID: 29756307.
Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124(18):3693-3705, 2018. e-Pub 2018. PMID: 30289966.
Ferrarotto R Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head Neck 40(8):1676-1684, 2018. e-Pub 2018. PMID: 29570891.
Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst 110(8):888-894, 2018. e-Pub 2018. PMID: 29346573.
Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68, 2018. e-Pub 2018. PMID: 29996921.
Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and immune- directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945-951, 2018. e-Pub 2018. PMID: 29742974.
Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P. A Phase 1 dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 29(7):1561-1568, 2018. e-Pub 2018. PMID: 29726923.
Ferrarotto R, William WN, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol 82:83-90, 2018. e-Pub 2018. PMID: 29909907.
Mays AC, Bell D, Ferrarotto R, Phan J, Roberts D, Fuller CD, Frank SJ, Raza SM, Kupferman ME, DeMonte F, Hanna EY, Su SY. Early Stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb. Laryngoscope 128(6):1274-1280, 2018. e-Pub 2018. PMID: 29226334.
Mott FE, Ferrarotto R, Nguyen T, Phan J. Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy. Oral Oncol 81:75-80, 2018. e-Pub 2018. PMID: 29884417.
Kamal M, Mohamed ASR, Fuller CD, Sturgis EM, Johnson FM, Morrison WH, Gunn GB, Hutcheson KA, Phan J, Volpe S, Ng SP, b Ferrarotto R, Frank SJ, Skinner HD, Rosenthal DI, Garden AS. Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. Cancer 124(7):1415-1427, 2018. e-Pub 2018. PMID: 29338089.
Kamal M, Ng SP, Eraj SA, Rock CD, Pham B, Messer JA, Garden AS, Morrison WH, Phan J, Frank SJ, El-Naggar AK, Johnson JM, Ginsberg LE, Ferrarotto R, Lewin JS, Hutcheson KA, Cardenas CE, Zafereo ME, Lai SY, Hessel AC, Weber RS, Gunn GB, Fuller CD, Mohamed ASR, Rosenthal DI. Three-Dimensional Imaging Assessment of Anatomic Invasion and Volumetric Considerations for Chemo/Radiotherapy-Based Laryngeal Preservation in T3 larynx Cancer. Oral Oncol 79:1-8, 2018. e-Pub 2018. PMID: 29598944.
Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2018. PMID: 29161986.
William WN, Feng L, Ferrarotto R Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol 77(6):1110-1113.e2, 2017. e-Pub 2017. PMID: 28964539.
MD Anderson Head MD, Working Group NCS, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Brandon Gunn G. Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65 years old. Radiat Oncol 12(1):186, 2017. e-Pub 2017. PMID: 29169353.
Ferrarotto R, Heymach JV. Taking it up a NOTCH: a novel subgroup of ACC is identified. Oncotarget 8(47):81725-81726, 2017. e-Pub 2017. PMID: 29137213.
MD Anderson Head MD, Working Group NCS, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Gunn GB. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65 years old. Radiat Oncol 12(1):150, 2017. e-Pub 2017. PMID: 28888224.
Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, Frank SJ, Fuller CD, Gunn GB, Kies MS, Glisson BS, Hanna EY. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck 39(8):1671-1679, 2017. e-Pub 2017. PMID: 28561956.
MD Anderson Head MD, Working Group NCS. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison. Radiother Oncol 124(2):232-239, 2017. e-Pub 2017. PMID: 28733053.
Shiao JC, Mohamed ASR, Messer JA, Hutcheson KA, Johnson JM, Enderling H, Kamal M, Warren BW, Pham B, Morrison WH, Zafereo ME, Hessel AC, Lai SY, Kies MS, Ferrarotto R, Garden AS, Schomer DF, Gunn GB, Phan J, Frank SJ, Beadle BM, Weber RS, Lewin JS, Rosenthal DI, Fuller CD. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck 39(8):1609-1620, 2017. e-Pub 2017. PMID: 28464542.
Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid 27(5):672-681, 2017. e-Pub 2017. PMID: 28068873.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol 35(3):JCO2016675264, 2017. e-Pub 2017. PMID: 27870570.
Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15(2):e1-7, 2016. e-Pub 2016. PMID: 26810202.
Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. J Oncol Pract 12(6):511-8, 2016. e-Pub 2016. PMID: 27288464.
Mauzo SH, Ferrarotto R, Bell D, Torres-Cabala CA, Tetzlaff MT, Prieto VG, Aung PP. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. J Clin Pathol 69(5):382-90, 2016. e-Pub 2016. PMID: 26818033.
Ferrarotto R, Heymach JV, Glisson BS. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Curr Opin Oncol 28(3):195-200, 2016. e-Pub 2016. PMID: 26974847.
Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res 22(7):1674-86, 2016. e-Pub 2016. PMID: 26597303.
MD Anderson Head MD, Working Group NCS. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol. e-Pub 2016. PMID: 26897515.
Massarelli E, Ferrarotto R, Glisson BS. New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic. Clin Cancer Res 21(17):3821-8, 2015. e-Pub 2015. PMID: 26330505.
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP-framework, overview, and design principles. Chin Clin Oncol 4(3):36, 2015. e-Pub 2015. PMID: 26408303.
Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, b Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2015. PMID: 25535726.
Bell D, Ferrarotto R, Fox MD, Roberts D, Hanna EY, Weber RS, El-Naggar AK. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther 16(6):834-8, 2015. e-Pub 2015. PMID: 25923130.
Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res 20(24):6570-81, 2014. e-Pub 2014. PMID: 25316813.
Ferrarotto R, Testa L, Riechelmann RP, Sahade M, Siqueira LT, Costa FP, Hoff PM. Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors. Rare Tumors 5(3):e35, 2013. e-Pub 2013. PMID: 24179647.
Ferrarotto R, Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer 48(6):820-6, 2012. e-Pub 2012. PMID: 22330318.
Ferrarotto R, Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz S. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer 10(3):178-82, 2011. e-Pub 2011. PMID: 21855039.
Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 30(1):67-78, 2010. e-Pub 2010. PMID: 20140479.

Invited Articles

Snyderman C, Foote R, Ferrarotto R. Paintal A. Olfactory neuroblastoma (esthesioneurroblastoma), 2021. e-Pub 2021.
DeMonte F, Hanna E, Ferrarotto R. Multidisciplinary Treatment Maximizes Outcomes for Malignant Tumors of the Anterior Skull Base. OncoLog 60(11-12), 2015. e-Pub 2015.

Review Articles

Araújo, AD, Lima-Souzade Lima-Souza, RA, Mariano, FV, Agaimy, A, Vander Poorten, V, Stenman, G, Piazza, C, Simpson, RH, Vargas, PA, Dos Santos-Silva, AR, de Castro Júnior, G, Ferrarotto, R, Skalova, A, Ferlito, A, Kowalski, LP. Integrative diagnostic approach to salivary gland tumors. Virchows Archiv 487(5):943-957, 2025. e-Pub 2025. PMID: 41134332.
Contrera, KJ, Reddy, PD, Helou, V, Myers, JN, Skinner, H, Ferrarotto, R, Myers, EN. The Evolution of Multidisciplinary Head and Neck Cancer Treatment. Laryngoscope 135(7):2255-2260, 2025. e-Pub 2025. PMID: 39960134.
Jiménez-Labaig, P, Lorini, L, Gurizzan, C, Kinloch, E, Burton, S, Forster, M, Metcalf, R, Ferrarotto, R, Bossi, P, O´leary, B, Hanna, GJ, Felip, E, Garcia, IB, Harrington, K. Clinical trials for patients with salivary gland cancers. Critical Reviews in Oncology/Hematology 211, 2025. e-Pub 2025. PMID: 40294876.
Contrera, KJ, Kansara, S, Goyal, N, Mady, LJ, Puram, SV, Young, GD, Zandberg, DP, Uppaluri, R, Ferrarotto, R, Holsinger, F, Ferris, R, Wenig, B, Curry, J. Neoadjuvant Therapy for Mucosal Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery 151(6):615-625, 2025. e-Pub 2025. PMID: 40272829.
Ferrari, M, Mularoni, F, Smussi, D, Gaudioso, P, Bonomo, P, Friborg, J, Ghi, MG, Gregoire, V, Harrington, K, Hunter, KD, Maroldi, R, Martino, R, Mesía, R, Peretti, G, Psyrri, A, Schindler, A, Succo, G, Szturz, P, Vilaseca, I, Nicolai, P, Bossi, P, Agarwal, JP, Ansarin, M, Argiris, A, Balermpas, P, Battisti, NL, Bellini, E, Bertolin, A, Carobbio, AC, Chiesa-Estomba, CM, Cirauqui, B, Crosetti, E, Oliveira, TB, Deganello, A, Dietz, A, Eriksen, JG, Eskander, A, Fakhry, N, Falco, A, Farina, D, Ferrarotto, R, Franzese, C, Ghosh Laskar, S, Golusinski, W, Hanna, EY, Irish, JC, Kiyota, N, Kowalski, LP, Krishnan, S, Lee, N, Leemans, CR, Licitra, L, Locati, LD, Machiels, JP, Marchi, F, Mattavelli, D, Mehanna, H, Mercante, G, Montalto, N, Morbini, P, O'Sullivan, B, Oliva, M, Orlandi, E, Paderno, A, Paleri, V, Pameijer, F, Perri, F, Persio, R, Piazza, C, Pointreau, Y, Presutti, L, Ravanelli, M, Rischin, D, Rodrigo, JP, Ruaro, A, Sanguineti, G, Simon, C, Siu, LL, Spreafico, A, Spriano, G, Taboni, S, Tassini, U, Tribius, S, Van Den Brekel, MW, Vander Poorten, V, Viros Porcuna, D. International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer. The lancet oncology 26(5):e264-e281, 2025. e-Pub 2025. PMID: 40318658.
Mores, AL, Pérez-de-Oliveira, ME, Normando, AC, Rodrigues-Oliveira, L, Marta, GN, Ferrarotto, R, Brandão, TB, Dos Santos-Silva, AR, Prado-Ribeiro, AC. Impact of cigarette taxes and prices in Latin America tobacco smoking prevalence. Oral Oncology Reports 11, 2024. e-Pub 2024.
Di Villeneuve L, Souza IL, Tolentino FDS, Ferrarotto R, Schvartsman G. Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease. Front Oncol 10:580141, 2020. e-Pub 2020. PMID: 33194707.
Shah M, Jomaa MK, Ferrarotto R, Yeung SJ, Hanna EY, Reyes-Gibby CC. Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head Neck 41(11):4036-4050, 2019. e-Pub 2019. PMID: 31414560.
Schvartsman G, Pinto NA, Bell D, Ferrarotto R. Salivary Gland Tumors: Molecular characterization and Therapeutic Advances for Metastatic Disease. Head Neck 41(1):239-247, 2019. e-Pub 2019. PMID: 30552848.
Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer 18(1):903, 2018. e-Pub 2018. PMID: 30231854.
Kamal M, Mohamed ASR, Volpe S, Zaveri J, Barrow MP, Gunn GB, Lai SY, Ferrarotto R, Lewin JS, Rosenthal DI, Jethanandani A, Meheissen MAM, Mulder SL, Cardenas CE, Fuller CD, Hutcheson KA, MD Anderson Head MD, Working Group NCS. Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. Radiother Oncol 128(3):442-451, 2018. e-Pub 2018. PMID: 29961581.
Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Res 7, 2018. e-Pub 2018. PMID: 31583077.
Schvartsman G, Ferrarotto R Massarelli E. Checkpoint inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol 8(6):460-473, 2016. e-Pub 2016. PMID: 27800034.
Ferrarotto R, Gold KA. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs 23(1):135-43, 2014. e-Pub 2014. PMID: 24266694.
Ferrarotto R, Hoff PM. Antiangiogenic drugs for colorectal cancer: exploring new possibilities. Clin Colorectal Cancer 12(1):1-7, 2013. e-Pub 2013. PMID: 22763196.
Ferrarotto R, Sabbaga J, Capareli FC, Saragiotto DF, Hoff PM. Best strategy in the approach of advanced colorectal cancer: aggressive or non-aggressive chemotherapy. Curr Colorectal Cancer Rep, 2012. e-Pub 2012.
Ferrarotto R, Schetino G, Freitas D, Capelozzi V, Hoff PM. Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature. Oncol Rev 4(2):101-06, 2010. e-Pub 2010.

Book Chapters

Wang, RJ, Bell, D, Ferrarotto, R, Weber, RS, Su, SY. Malignant Tumors, 286-301, 2021.
Ferrarotto R, Kupferman ME, Garden AS, Kies MS In: Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei III. In: Neoplasms of the Head and Neck, E. Cancer Medicine 9th edition. Ed: Wiley Health Science, 2015.
Ferrarotto R, Simon G. Non-Small Cell Lung Cancers (NSCLC) with Mutations in BRAF. In: Lung Cancer: Fourth edition. Vol. 9781118468746, 2014.
Ferrarotto R, Hernardez BH, Ramirez JAF, Serrano CV, Mady C. In: Tromboembolismo arterial e venoso: risco aumentado no paciente oncologico Serie Incor de Cardiologia Vol.5, Cardio-Oncologia - Temas Comums entre a Cardiologia e a Oncologia, Ed: Atheneu, Sao Paulo, 2013.
Ferrarotto R, Hoff PM, Chammas R, Novis Y, Filho VO. Antimetabolites. In: Tratado de Oncologia, 2012.
Ferrarotto R, Pavan T, Hoff PM, Katz A. In: Cancer Colorretal. Oncologia clinica: tratamento baseado em evidencia,1st edition, Sao Paulo, 2012.
Massarelli E, Piha-Paul S, Goswami S, Marcelo-Lewis K, Ferrarotto R. Handbook of Targeted Cancer Therapy. Ed. In: Head and Neck Cancer. In: Karp D, Falchook GS.
Ferrarotto R. Chemotherapy in Temporal Bone Cancer. In: Temporal Bone Cancer.
Frank SJ, Ferrarotto R, Hanna EY. In: Cancer of the Nasal Vestibule, Nasal Cavity, and Paranasal Sinuses. In: DeVita, Hellman and Rosenberg’s Principles and Practice of Oncology; 12th Edition, Ed: Wolters Kluwer,.

Letters to the Editor

de Sousa, LG, Liu, S, Bhosale, P, Altan, M, Darbonne, WC, Schulze, K, Dervin, S, Yun, C, Mahvash, A, Verma, A, Futreal, A, Gite, S, Parra Cuentas, ER, Cho, WC, Wistuba, II, Yao, JC, Woodman, SE, Halperin, DM, Ferrarotto, R. Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma. Oral Oncology 151, 2024.